Kunshan RiboQuark Raises $7.5 Million For siRNA Projects
1/10/2014 3:53:59 PM
by Richard Daverman, PhD
January 10, 2014 -- Kunshan RiboQuark Pharma, a siRNA joint venture formed by Suzhou Ribo Life Science and Quark Pharma of California, raised almost 45 million RMB ($7.5 million) in a series A round. The financing was led by BVCF, formerly known as BioVeda China. RiboQuark will use the money to further clinical development of QPI-1007, a siRNA ocular neuroprotectant developed by Quark for which the JV owns China rights. More details....
Help employers find you! Check out all the jobs and post your resume.
comments powered by